Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00450203
Status:
UNKNOWN
Last Update Posted:
2016-12-01
First Post:
2007-03-20
Brief Title:
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
Sponsor:
Professor David Cunningham
Organization:
Medical Research Council
Organization Data
Organization:
Medical Research Council
Class:
OTHER_GOV
Study ID:
CDR0000536013
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Professor David Cunningham
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Professor David Cunningham
Responsible Party Title:
ST03 Chief Investigator Professor David Cunningham
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Medical Research Council
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
| Cancer Research UK | OTHER |
| Roche Pharma AG | INDUSTRY |